Hepatic fibrosis and gene expression changes induced by praziquantel treatment during immune modulation of Schistosoma japonicum infection

T. F. Kresina, Q. He, Mark A Zern, M. A. Zern

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In the present study fibrogenic gene expression was determined in murine Schistosoma japonicum infection during the progression of immune modulation of infection and following chemotherapy during the course of immune modulation. Histomorphometric analysis of granuloma size and collagen deposition revealed peak granuloma size in acute infection (5 weeks) and peak hepatic collagen content at 16 weeks of infection. Peak Type I collagen gene expression was concomitant with TGF-β1 gene expression at 8-11 weeks. Chemotherapy during either acute (9 weeks) or chronic (24, 28 weeks) infection resulted in increased collagen deposition and increased gene expression of Type I collagen and TGF-β1. However, chemotherapy at 14-16 weeks resulted in decreased levels of TGF-β1 gene expression and essentially minimal change in Type I collagen deposition and gene expression. These data indicate that chemotherapy of schistosomiasis japonica does not reverse hepatic fibrogenesis when administered in acute infection - when granuloma size is maximal - or in chronic infection. However, a beneficial effect on hepatic fibrogenesis is seen when chemotherapy is administered at 14-16 weeks post-infection, a time of decreasing granuloma size and maximal hepatic collagen content. Thus the ability to reverse schistosomal-induced hepatic fibrogenesis by chemotherapy may depend on disease stage.

Original languageEnglish (US)
Pages (from-to)397-404
Number of pages8
JournalParasitology
Volume107
Issue number4
StatePublished - 1993
Externally publishedYes

Fingerprint

Schistosoma japonicum
praziquantel
Praziquantel
liver cirrhosis
Fibrosis
collagen
drug therapy
Gene Expression
gene expression
Liver
granuloma
Infection
Granuloma
Drug Therapy
infection
Collagen
Collagen Type I
liver
Therapeutics
Schistosomiasis japonica

Keywords

  • fibrogenic gene expression
  • immune modulation
  • praziquantel
  • Schistosoma japonicum

ASJC Scopus subject areas

  • Immunology
  • Parasitology

Cite this

Hepatic fibrosis and gene expression changes induced by praziquantel treatment during immune modulation of Schistosoma japonicum infection. / Kresina, T. F.; He, Q.; Zern, Mark A; Zern, M. A.

In: Parasitology, Vol. 107, No. 4, 1993, p. 397-404.

Research output: Contribution to journalArticle

@article{83313747279e4b28b51e587a75e38e36,
title = "Hepatic fibrosis and gene expression changes induced by praziquantel treatment during immune modulation of Schistosoma japonicum infection",
abstract = "In the present study fibrogenic gene expression was determined in murine Schistosoma japonicum infection during the progression of immune modulation of infection and following chemotherapy during the course of immune modulation. Histomorphometric analysis of granuloma size and collagen deposition revealed peak granuloma size in acute infection (5 weeks) and peak hepatic collagen content at 16 weeks of infection. Peak Type I collagen gene expression was concomitant with TGF-β1 gene expression at 8-11 weeks. Chemotherapy during either acute (9 weeks) or chronic (24, 28 weeks) infection resulted in increased collagen deposition and increased gene expression of Type I collagen and TGF-β1. However, chemotherapy at 14-16 weeks resulted in decreased levels of TGF-β1 gene expression and essentially minimal change in Type I collagen deposition and gene expression. These data indicate that chemotherapy of schistosomiasis japonica does not reverse hepatic fibrogenesis when administered in acute infection - when granuloma size is maximal - or in chronic infection. However, a beneficial effect on hepatic fibrogenesis is seen when chemotherapy is administered at 14-16 weeks post-infection, a time of decreasing granuloma size and maximal hepatic collagen content. Thus the ability to reverse schistosomal-induced hepatic fibrogenesis by chemotherapy may depend on disease stage.",
keywords = "fibrogenic gene expression, immune modulation, praziquantel, Schistosoma japonicum",
author = "Kresina, {T. F.} and Q. He and Zern, {Mark A} and Zern, {M. A.}",
year = "1993",
language = "English (US)",
volume = "107",
pages = "397--404",
journal = "Parasitology",
issn = "0031-1820",
publisher = "Cambridge University Press",
number = "4",

}

TY - JOUR

T1 - Hepatic fibrosis and gene expression changes induced by praziquantel treatment during immune modulation of Schistosoma japonicum infection

AU - Kresina, T. F.

AU - He, Q.

AU - Zern, Mark A

AU - Zern, M. A.

PY - 1993

Y1 - 1993

N2 - In the present study fibrogenic gene expression was determined in murine Schistosoma japonicum infection during the progression of immune modulation of infection and following chemotherapy during the course of immune modulation. Histomorphometric analysis of granuloma size and collagen deposition revealed peak granuloma size in acute infection (5 weeks) and peak hepatic collagen content at 16 weeks of infection. Peak Type I collagen gene expression was concomitant with TGF-β1 gene expression at 8-11 weeks. Chemotherapy during either acute (9 weeks) or chronic (24, 28 weeks) infection resulted in increased collagen deposition and increased gene expression of Type I collagen and TGF-β1. However, chemotherapy at 14-16 weeks resulted in decreased levels of TGF-β1 gene expression and essentially minimal change in Type I collagen deposition and gene expression. These data indicate that chemotherapy of schistosomiasis japonica does not reverse hepatic fibrogenesis when administered in acute infection - when granuloma size is maximal - or in chronic infection. However, a beneficial effect on hepatic fibrogenesis is seen when chemotherapy is administered at 14-16 weeks post-infection, a time of decreasing granuloma size and maximal hepatic collagen content. Thus the ability to reverse schistosomal-induced hepatic fibrogenesis by chemotherapy may depend on disease stage.

AB - In the present study fibrogenic gene expression was determined in murine Schistosoma japonicum infection during the progression of immune modulation of infection and following chemotherapy during the course of immune modulation. Histomorphometric analysis of granuloma size and collagen deposition revealed peak granuloma size in acute infection (5 weeks) and peak hepatic collagen content at 16 weeks of infection. Peak Type I collagen gene expression was concomitant with TGF-β1 gene expression at 8-11 weeks. Chemotherapy during either acute (9 weeks) or chronic (24, 28 weeks) infection resulted in increased collagen deposition and increased gene expression of Type I collagen and TGF-β1. However, chemotherapy at 14-16 weeks resulted in decreased levels of TGF-β1 gene expression and essentially minimal change in Type I collagen deposition and gene expression. These data indicate that chemotherapy of schistosomiasis japonica does not reverse hepatic fibrogenesis when administered in acute infection - when granuloma size is maximal - or in chronic infection. However, a beneficial effect on hepatic fibrogenesis is seen when chemotherapy is administered at 14-16 weeks post-infection, a time of decreasing granuloma size and maximal hepatic collagen content. Thus the ability to reverse schistosomal-induced hepatic fibrogenesis by chemotherapy may depend on disease stage.

KW - fibrogenic gene expression

KW - immune modulation

KW - praziquantel

KW - Schistosoma japonicum

UR - http://www.scopus.com/inward/record.url?scp=0027515784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027515784&partnerID=8YFLogxK

M3 - Article

C2 - 7506405

AN - SCOPUS:0027515784

VL - 107

SP - 397

EP - 404

JO - Parasitology

JF - Parasitology

SN - 0031-1820

IS - 4

ER -